Recent advances in systemic therapy for biliary tract cancer: Evidence from Japan and recommendations in guidelines.
Systemic therapy for biliary tract cancer (BTC) has evolved substantially over the past two decades. Gemcitabine plus cisplatin was established as the global standard first-line regimen, followed by further optimization through alternative doublets, intensified triplet chemotherapy, and the recent introduction of immun...